APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dolutegravir

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dolutegravir Market Outlook and Growth Opportunities 2026

23 December 2025192 pages

Choose your research edition.

Industry ResearchDolutegravir Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Dolutegravir Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Dolutegravir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dolutegravir Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Dolutegravir Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Dolutegravir market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dolutegravir market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dolutegravir market include Shanghai Desano Pharmaceuticals, Mylan, ViiV Healthcare (GSK), LAURUS Labs, Aurobindo Pharma and Adcock Ingram Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dolutegravir market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dolutegravir and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dolutegravir sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dolutegravir market size, projected growth trends, production technologies, key applications, and end-use industries.

Dolutegravir Segment by Company

Shanghai Desano Pharmaceuticals

Mylan

ViiV Healthcare (GSK)

LAURUS Labs

Aurobindo Pharma

Adcock Ingram Limited

Dolutegravir Segment by Type

10mg Tablets

50mg Tablets

Dolutegravir Segment by Application

Prevent HIV Infection Following Potential Exposure

Others

Dolutegravir Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dolutegravir status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dolutegravir market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dolutegravir significant trends, drivers, influence factors in global and regions.

6. To analyze Dolutegravir competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dolutegravir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dolutegravir and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dolutegravir.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dolutegravir market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dolutegravir industry.

Chapter 3: Detailed analysis of Dolutegravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dolutegravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dolutegravir in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dolutegravir Industry Trends Table 2. Dolutegravir Industry Drivers Table 3. Dolutegravir Industry Opportunities and Challenges Table 4. Dolutegravir Industry Restraints Table 5. Global Dolutegravir Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dolutegravir Revenue Share by Company (2021-2026) Table 7. Global Dolutegravir Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Dolutegravir Sales Volume Share by Company (2021-2026) Table 9. Global Dolutegravir Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Dolutegravir Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dolutegravir Key Company Manufacturing Base & Headquarters Table 12. Global Dolutegravir Company, Product Type & Application Table 13. Global Dolutegravir Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dolutegravir by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10mg Tablets Table 18. Significant Companies of 50mg Tablets Table 19. Global Dolutegravir Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Dolutegravir Sales Volume by Type (2021-2026) & (k pcs) Table 21. Global Dolutegravir Sales Volume by Type (2027-2032) & (k pcs) Table 22. Global Dolutegravir Sales Volume Share by Type (2021-2026) Table 23. Global Dolutegravir Sales Volume Share by Type (2027-2032) Table 24. Global Dolutegravir Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dolutegravir Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Dolutegravir Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Dolutegravir Sales Value Share by Type (2021-2026) Table 28. Global Dolutegravir Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Prevent HIV Infection Following Potential Exposure Table 30. Significant Companies of Others Table 31. Global Dolutegravir Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 32. Global Dolutegravir Sales Volume by Application (2021-2026) & (k pcs) Table 33. Global Dolutegravir Sales Volume by Application (2027-2032) & (k pcs) Table 34. Global Dolutegravir Sales Volume Share by Application (2021-2026) Table 35. Global Dolutegravir Sales Volume Share by Application (2027-2032) Table 36. Global Dolutegravir Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Dolutegravir Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Dolutegravir Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Dolutegravir Sales Value Share by Application (2021-2026) Table 40. Global Dolutegravir Sales Value Share by Application (2027-2032) Table 41. Global Dolutegravir Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 42. Global Dolutegravir Sales by Region (2021-2026) & (k pcs) Table 43. Global Dolutegravir Sales Market Share by Region (2021-2026) Table 44. Global Dolutegravir Sales by Region (2027-2032) & (k pcs) Table 45. Global Dolutegravir Sales Market Share by Region (2027-2032) Table 46. Global Dolutegravir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Dolutegravir Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Dolutegravir Sales Value Share by Region (2021-2026) Table 49. Global Dolutegravir Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Dolutegravir Sales Value Share by Region (2027-2032) Table 51. Global Dolutegravir Market Average Price (US$/pcs) by Region (2021-2026) Table 52. Global Dolutegravir Market Average Price (US$/pcs) by Region (2027-2032) Table 53. Global Dolutegravir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 54. Global Dolutegravir Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Dolutegravir Sales by Country (2021-2026) & (k pcs) Table 56. Global Dolutegravir Sales Market Share by Country (2021-2026) Table 57. Global Dolutegravir Sales by Country (2027-2032) & (k pcs) Table 58. Global Dolutegravir Sales Market Share by Country (2027-2032) Table 59. Global Dolutegravir Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Dolutegravir Sales Value Market Share by Country (2021-2026) Table 61. Global Dolutegravir Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Dolutegravir Sales Value Market Share by Country (2027-2032) Table 63. Shanghai Desano Pharmaceuticals Company Information Table 64. Shanghai Desano Pharmaceuticals Business Overview Table 65. Shanghai Desano Pharmaceuticals Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 66. Shanghai Desano Pharmaceuticals Dolutegravir Product Portfolio Table 67. Shanghai Desano Pharmaceuticals Recent Development Table 68. Mylan Company Information Table 69. Mylan Business Overview Table 70. Mylan Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 71. Mylan Dolutegravir Product Portfolio Table 72. Mylan Recent Development Table 73. ViiV Healthcare (GSK) Company Information Table 74. ViiV Healthcare (GSK) Business Overview Table 75. ViiV Healthcare (GSK) Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 76. ViiV Healthcare (GSK) Dolutegravir Product Portfolio Table 77. ViiV Healthcare (GSK) Recent Development Table 78. LAURUS Labs Company Information Table 79. LAURUS Labs Business Overview Table 80. LAURUS Labs Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 81. LAURUS Labs Dolutegravir Product Portfolio Table 82. LAURUS Labs Recent Development Table 83. Aurobindo Pharma Company Information Table 84. Aurobindo Pharma Business Overview Table 85. Aurobindo Pharma Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 86. Aurobindo Pharma Dolutegravir Product Portfolio Table 87. Aurobindo Pharma Recent Development Table 88. Adcock Ingram Limited Company Information Table 89. Adcock Ingram Limited Business Overview Table 90. Adcock Ingram Limited Dolutegravir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 91. Adcock Ingram Limited Dolutegravir Product Portfolio Table 92. Adcock Ingram Limited Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Dolutegravir Distributors List Table 96. Dolutegravir Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Dolutegravir Product Image Figure 2. Global Dolutegravir Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dolutegravir Sales (2021-2032) & (k pcs) Figure 5. Global Dolutegravir Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Dolutegravir Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10mg Tablets Image Figure 10. 50mg Tablets Image Figure 11. Global Dolutegravir Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Dolutegravir Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Dolutegravir Sales Volume Share by Type (2021-2032) Figure 14. Global Dolutegravir Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Dolutegravir Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Dolutegravir Sales Value Share by Type (2021-2032) Figure 17. Prevent HIV Infection Following Potential Exposure Image Figure 18. Others Image Figure 19. Global Dolutegravir Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 20. Global Dolutegravir Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Dolutegravir Sales Volume Share by Application (2021-2032) Figure 22. Global Dolutegravir Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Dolutegravir Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Dolutegravir Sales Value Share by Application (2021-2032) Figure 25. Global Dolutegravir Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 26. Global Dolutegravir Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Dolutegravir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Dolutegravir Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 30. North America Dolutegravir Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Dolutegravir Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Dolutegravir Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 36. South America Dolutegravir Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Dolutegravir Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Dolutegravir Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Dolutegravir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Dolutegravir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Dolutegravir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Dolutegravir Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Dolutegravir Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 10mg Tablets
  • 50mg Tablets
Applications
  • Prevent HIV Infection Following Potential Exposure
  • Others
Companies covered
  • Shanghai Desano Pharmaceuticals
  • Mylan
  • ViiV Healthcare (GSK)
  • LAURUS Labs
  • Aurobindo Pharma
  • Adcock Ingram Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dolutegravir Sales Value (2021-2032)
  4. 1.2.2 Global Dolutegravir Sales Volume (2021-2032)
  5. 1.2.3 Global Dolutegravir Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dolutegravir Market Dynamics
  1. 2.1 Dolutegravir Industry Trends
  2. 2.2 Dolutegravir Industry Drivers
  3. 2.3 Dolutegravir Industry Opportunities and Challenges
  4. 2.4 Dolutegravir Industry Restraints
3 Dolutegravir Market by Company
  1. 3.1 Global Dolutegravir Company Revenue Ranking in 2025
  2. 3.2 Global Dolutegravir Revenue by Company (2021-2026)
  3. 3.3 Global Dolutegravir Sales Volume by Company (2021-2026)
  4. 3.4 Global Dolutegravir Average Price by Company (2021-2026)
  5. 3.5 Global Dolutegravir Company Ranking (2024-2026)
  6. 3.6 Global Dolutegravir Company Manufacturing Base and Headquarters
  7. 3.7 Global Dolutegravir Company Product Type and Application
  8. 3.8 Global Dolutegravir Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dolutegravir Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dolutegravir Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dolutegravir Market by Type
  1. 4.1 Dolutegravir Type Introduction
  2. 4.1.1 10mg Tablets
  3. 4.1.2 50mg Tablets
  4. 4.2 Global Dolutegravir Sales Volume by Type
  5. 4.2.1 Global Dolutegravir Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Dolutegravir Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Dolutegravir Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Dolutegravir Sales Value by Type
  9. 4.3.1 Global Dolutegravir Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Dolutegravir Sales Value by Type (2021-2032)
  11. 4.3.3 Global Dolutegravir Sales Value Share by Type (2021-2032)
5 Dolutegravir Market by Application
  1. 5.1 Dolutegravir Application Introduction
  2. 5.1.1 Prevent HIV Infection Following Potential Exposure
  3. 5.1.2 Others
  4. 5.2 Global Dolutegravir Sales Volume by Application
  5. 5.2.1 Global Dolutegravir Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Dolutegravir Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Dolutegravir Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Dolutegravir Sales Value by Application
  9. 5.3.1 Global Dolutegravir Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Dolutegravir Sales Value by Application (2021-2032)
  11. 5.3.3 Global Dolutegravir Sales Value Share by Application (2021-2032)
6 Dolutegravir Regional Sales and Value Analysis
  1. 6.1 Global Dolutegravir Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dolutegravir Sales by Region (2021-2032)
  3. 6.2.1 Global Dolutegravir Sales by Region: 2021-2026
  4. 6.2.2 Global Dolutegravir Sales by Region (2027-2032)
  5. 6.3 Global Dolutegravir Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dolutegravir Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dolutegravir Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dolutegravir Sales Value by Region (2027-2032)
  9. 6.5 Global Dolutegravir Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dolutegravir Sales Value (2021-2032)
  12. 6.6.2 North America Dolutegravir Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dolutegravir Sales Value (2021-2032)
  15. 6.7.2 Europe Dolutegravir Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dolutegravir Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dolutegravir Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dolutegravir Sales Value (2021-2032)
  21. 6.9.2 South America Dolutegravir Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dolutegravir Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dolutegravir Sales Value Share by Country, 2025 VS 2032
7 Dolutegravir Country-level Sales and Value Analysis
  1. 7.1 Global Dolutegravir Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dolutegravir Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dolutegravir Sales by Country (2021-2032)
  4. 7.3.1 Global Dolutegravir Sales by Country (2021-2026)
  5. 7.3.2 Global Dolutegravir Sales by Country (2027-2032)
  6. 7.4 Global Dolutegravir Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dolutegravir Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dolutegravir Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dolutegravir Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dolutegravir Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dolutegravir Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dolutegravir Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dolutegravir Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dolutegravir Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dolutegravir Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dolutegravir Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dolutegravir Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dolutegravir Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dolutegravir Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dolutegravir Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dolutegravir Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dolutegravir Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dolutegravir Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dolutegravir Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dolutegravir Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dolutegravir Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dolutegravir Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dolutegravir Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dolutegravir Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dolutegravir Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dolutegravir Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dolutegravir Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dolutegravir Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dolutegravir Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dolutegravir Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dolutegravir Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dolutegravir Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dolutegravir Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dolutegravir Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dolutegravir Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dolutegravir Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dolutegravir Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dolutegravir Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dolutegravir Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dolutegravir Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dolutegravir Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dolutegravir Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dolutegravir Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dolutegravir Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dolutegravir Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dolutegravir Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dolutegravir Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dolutegravir Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dolutegravir Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dolutegravir Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dolutegravir Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dolutegravir Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dolutegravir Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dolutegravir Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dolutegravir Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dolutegravir Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dolutegravir Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dolutegravir Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dolutegravir Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dolutegravir Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dolutegravir Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dolutegravir Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dolutegravir Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dolutegravir Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dolutegravir Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dolutegravir Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dolutegravir Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dolutegravir Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dolutegravir Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dolutegravir Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dolutegravir Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dolutegravir Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dolutegravir Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dolutegravir Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dolutegravir Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dolutegravir Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dolutegravir Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dolutegravir Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dolutegravir Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dolutegravir Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dolutegravir Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dolutegravir Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dolutegravir Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dolutegravir Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dolutegravir Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dolutegravir Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dolutegravir Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Desano Pharmaceuticals
  2. 8.1.1 Shanghai Desano Pharmaceuticals Company Information
  3. 8.1.2 Shanghai Desano Pharmaceuticals Business Overview
  4. 8.1.3 Shanghai Desano Pharmaceuticals Dolutegravir Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Desano Pharmaceuticals Dolutegravir Product Portfolio
  6. 8.1.5 Shanghai Desano Pharmaceuticals Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Dolutegravir Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Dolutegravir Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 ViiV Healthcare (GSK)
  14. 8.3.1 ViiV Healthcare (GSK) Company Information
  15. 8.3.2 ViiV Healthcare (GSK) Business Overview
  16. 8.3.3 ViiV Healthcare (GSK) Dolutegravir Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 ViiV Healthcare (GSK) Dolutegravir Product Portfolio
  18. 8.3.5 ViiV Healthcare (GSK) Recent Developments
  19. 8.4 LAURUS Labs
  20. 8.4.1 LAURUS Labs Company Information
  21. 8.4.2 LAURUS Labs Business Overview
  22. 8.4.3 LAURUS Labs Dolutegravir Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 LAURUS Labs Dolutegravir Product Portfolio
  24. 8.4.5 LAURUS Labs Recent Developments
  25. 8.5 Aurobindo Pharma
  26. 8.5.1 Aurobindo Pharma Company Information
  27. 8.5.2 Aurobindo Pharma Business Overview
  28. 8.5.3 Aurobindo Pharma Dolutegravir Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Aurobindo Pharma Dolutegravir Product Portfolio
  30. 8.5.5 Aurobindo Pharma Recent Developments
  31. 8.6 Adcock Ingram Limited
  32. 8.6.1 Adcock Ingram Limited Company Information
  33. 8.6.2 Adcock Ingram Limited Business Overview
  34. 8.6.3 Adcock Ingram Limited Dolutegravir Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Adcock Ingram Limited Dolutegravir Product Portfolio
  36. 8.6.5 Adcock Ingram Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dolutegravir Value Chain Analysis
  2. 9.1.1 Dolutegravir Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dolutegravir Sales Mode & Process
  6. 9.2 Dolutegravir Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dolutegravir Distributors
  9. 9.2.3 Dolutegravir Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst